Yüklüyor......
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV) disease; however, conclusive evidence that glycemic control leads to improved cardiovascular outcomes is lacking. Saxagliptin is a potent, selective dipeptidyl peptidase-4 inhibitor approved as an adjunct to diet...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3277488/ https://ncbi.nlm.nih.gov/pubmed/22248301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2840-11-6 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|